Manon Boisclair was recently appointed to the role of Chief Commercial Officer of Syantra, where she will be responsible for the launch-readiness initiatives including the development and implementation of the global commercial and regulatory strategies of the Syantra solutions. Manon brings to Syantra a vast expertise in global operations, medical/marketing strategy, oncology product launches, and managerial experience in the BioPharma industry.
“I’m thrilled to join Syantra and work alongside an amazing team while building upon the positive momentum of precision medicine and liquid biopsy in oncology,” said Boisclair. “This is a unique opportunity to be trailblazers making a difference in early breast cancer detection with the goal to change the course of the disease for patients and their families.”
Manon has extensive expertise in business development, governance and private equity fundraising. She is also on the board of two privately owned MedTech companies as well as non-for-profit organizations including the Canadian Cancer Society. In addition to her EMBA from McGill-HEC Montréal, Manon has a master’s degree in nursing from University of Montreal, she is a certified corporate board director from Harvard Business School and the Institute of Corporate Directors.
About Syantra Inc.
Syantra Inc. is a precision healthcare company whose flagship product in the molecular diagnostic sector, Syantra DX | Breast Cancer, is a novel method of detecting breast cancer that uses a suite of biomarkers and artificial intelligence-generated algorithms to provide a positive or negative result.
Full press release; https://www.syantra.com/syantra-appoints-manon-boisclair-as-chief-commercial-officer
